Horizon backs Emalex

Horizon Technology Finance Corporation has provided a $15 million venture loan facility to Chicago-based Emalex Biosciences, a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this